02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
14:58 , May 30, 2019 |  BioCentury  |  Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
17:12 , May 17, 2019 |  BC Extra  |  Financial News

Tools4Patient raises €4M to refine, expand placebo response analytics

As it seeks to apply its placebo response measurement tool to new therapeutic areas beyond pain, Tools4Patient has tapped investors for a €4 million ($4.5 million) series B round. The company's Placebell technology uses an...
21:44 , May 7, 2019 |  BC Extra  |  Preclinical News

May 7 Preclinical Quick Takes: Single-cell computation, DARPA

Sensitive analysis of big single-cell data sets  A “geometric sketch” algorithm could be used to sensitively profile large sets of single-cell RNA sequencing data without sacrificing transcriptional diversity, according to a study from Massachusetts Institute...
18:03 , May 2, 2019 |  BC Innovations  |  Translation in Brief

From MSI-high to MSI-higher

A study in Science offers more clues to the consistent but poorly defined link between tumor mutation load and checkpoint inhibitor response. The data could explain why less than half of patients with MSI-high status...
19:16 , Apr 26, 2019 |  BioCentury  |  Product Development

For patients’ sake, collaborate already

Cancer immunotherapy companies must stop squandering the most precious stakeholder, patients, and collaborate now on platform trials to test new combination regimens. A straightforward platform trial design that tests different combo partners with PD-1/PD-L1 agents...
22:58 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
17:18 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...